I 
114TH CONGRESS 
1ST SESSION H. R. 2730 
To establish the National Prostate Cancer Council for improved screening, 
early detection, assessment, and monitoring of prostate cancer, and to 
direct the development and implementation of a national strategic plan 
to expedite advancement of diagnostic tools and the transfer of such 
tools to patients. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 11, 2015 
Mr. BUTTERFIELD (for himself, Mr. MCCAUL, Mr. CUMMINGS, and Mr. 
JONES) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To establish the National Prostate Cancer Council for im-
proved screening, early detection, assessment, and moni-
toring of prostate cancer, and to direct the development 
and implementation of a national strategic plan to expe-
dite advancement of diagnostic tools and the transfer 
of such tools to patients. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘National Prostate Can-
cer Plan Act’’. 
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS
SEC. 2. NATIONAL PROSTATE CANCER COUNCIL. 
(a) ESTABLISHMENT.—There is established in the 
Office of the Secretary of Health and Human Services (re-
ferred to in this section as the ‘‘Secretary’’) the National 
Prostate Cancer Council on Screening, Early Detection, 
Assessment, and Monitoring of Prostate Cancer (referred 
to in this Act as the ‘‘Council’’). 
(b) PURPOSE
OF
THE
COUNCIL.—The Council 
shall— 
(1) develop and implement a national strategic 
plan for the accelerated creation, advancement, and 
testing of diagnostic tools to improve screening, 
early detection, assessment, and monitoring of pros-
tate cancer, including— 
(A) early detection of aggressive prostate 
cancer to save lives; 
(B) monitoring of tumor response to treat-
ment, including recurrence and progression; and 
(C) accurate assessment and surveillance 
of indolent disease to reduce unnecessary biop-
sies and treatment; 
(2) provide information and coordination of 
prostate cancer research and services across all Fed-
eral agencies; 
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS
(3) review diagnostic tools and their overall ef-
fectiveness at screening, detecting, assessing, and 
monitoring of prostate cancer; 
(4) evaluate all programs in prostate cancer 
that are in existence on the date of enactment of 
this Act, including Federal budget requests and ap-
provals and public-private partnerships; 
(5) submit an annual report to the Secretary 
and Congress on the creation and implementation of 
the national strategic plan under paragraph (1); and 
(6) ensure the inclusion of men at high-risk for 
prostate cancer, including men from ethnic and ra-
cial populations and men who are least likely to re-
ceive care, in clinical, research, and service efforts, 
with the purpose of decreasing health disparities. 
(c) MEMBERSHIP.— 
(1) FEDERAL MEMBERS.—The Council shall be 
led by the Secretary or designee and comprised of 
the following experts: 
(A) Two representatives of the National 
Institutes of Health, including 1 representative 
of the National Institute of Biomedical Imaging 
and Bioengineering and 1 representative of the 
National Cancer Institute. 
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS
(B) A representative of the Centers for 
Disease Control and Prevention. 
(C) A representative of the Centers for 
Medicare and Medicaid Services. 
(D) A designee of the Director of the De-
partment of Defense Congressionally Directed 
Medical Research Program. 
(E) A designee of the Director of the Of-
fice of Minority Health. 
(F) A representative of the Food and Drug 
Administration. 
(G) A representative of the Agency for 
Healthcare Research and Quality. 
(2) NON-FEDERAL MEMBERS.—In addition to 
the members described in paragraph (1), the Council 
shall include 14 expert members from outside the 
Federal Government, which shall include— 
(A) 6 prostate cancer patient advocates, 
including— 
(i) 2 patient-survivors; 
(ii) 2 caregivers of prostate cancer pa-
tients; and 
(iii) 2 representatives from national 
prostate cancer disease organizations that 
fund research or have demonstrated experi-
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS
ence in providing assistance to patients, 
families, and medical professionals, includ-
ing information on health care options, 
education, and referral; and 
(B) 8 health care stakeholders with specific 
expertise in prostate cancer research in the crit-
ical areas of clinical expertise, including medical 
oncology, radiology, radiation oncology, urology, 
and pathology. 
(d) MEETINGS.—The Council shall meet quarterly 
and meetings shall be open to the public. 
(e) ADVICE.—The Council shall advise the Secretary, 
or the Secretary’s designee. 
(f) ANNUAL REPORT.—The Council shall submit an-
nual reports, beginning not later than 1 year after the 
date of enactment of this Act, to the Secretary or the Sec-
retary’s designee and to Congress. The annual report shall 
include— 
(1) in the first year— 
(A) an evaluation of all federally funded ef-
forts in prostate cancer research and gaps relat-
ing to the development and validation of diag-
nostic tools for prostate cancer; and 
(B) recommendations for priority actions 
to expand, eliminate, coordinate, or condense 
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS
programs based on the performance, mission, 
and purpose of the programs; and 
(2) annually thereafter for 5 years— 
(A) an outline for the development and im-
plementation of a national research plan for 
creation and validation of accurate diagnostic 
tools to improve prostate cancer care in accord-
ance with subsection (a); 
(B) roles for the National Cancer Institute, 
National Institute on Minority Health and 
Health Disparities, and the Office on Minority 
Health of the Department of Health and 
Human Services; 
(C) an analysis of the disparities in the in-
cidence and mortality rates of prostate cancer 
in men at high risk of the disease, including in-
dividuals with family history, increasing age, or 
African-American heritage; and 
(D) a review of the progress towards the 
realization of the proposed strategic plan. 
(g) TERMINATION.—The Council shall terminate on 
December 31, 2020. 
Æ 
VerDate Sep 11 2014 
02:24 Jun 16, 2015
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H2730.IH
H2730
SSpencer on DSK4SPTVN1PROD with BILLS